Comparing and contrasting the use of nanoparticle-assisted drug-delivery of antidepressants to that of the gold standard


  • Oscar Melendez Calabasas High School



Nanoparticles, drug delivery, blood-brain barrier, intranasal, antidepressant, encapsulation, Solid-lipid-nanoparticle, alginate nanoparticle, controlled release, depression


Nanoparticles (NP) are small-scale particles of elements at a scale that ranges between 1 to 100 nanometers. NP can be used to benefit drug delivery to the brain due to its ability to efficiently cross the blood-brain barrier (BBB). Depression is a widespread neuropsychiatric disorder with treatments that embody numerous flaws and shortcomings. A potential solution to this lack of treatment was pondered. NPs' ability to be implemented within antidepressants through encapsulation methods was investigated and the effects of NPs on the efficacy of the antidepressants were analyzed. Connections between the formulations of multiple NPs were made. Previous experiments and research regarding numerous NPs and how they were used to aid numerous types of antidepressants to treat various mental ailments were selected and analyzed thoroughly. From these findings, it was shown that various NP encapsulation and assistance methods can increase the efficacy of antidepressants, and potential implications of such findings were analyzed. 


Download data is not yet available.


Metrics Loading ...

References or Bibliography

American Psychological Association. (2021, November). Depression and anxiety escalate during COVID. Monitor on Psychology.

American Psychological Association. (2021, October 19). Demand for mental health treatment continues to increase, say psychologists.

Bayda, S., Hadla, M., Palazzolo, S., & Caligiuri, I. (2019). The history of nanoscience and nanotechnology: From chemical-physical applications to nanomedicine. Molecules (Basel, Switzerland), 24(3), 429.

Cleveland Clinic. (n.d.). Gamma-aminobutyric acid (GABA): What it is, function & benefits.

Daneman, R., & Prat, A. (2015). The blood-brain barrier. Cold Spring Harbor perspectives in biology, 7(1), a020412.

Haque, S., Md Sajidul Islam, M., Al-Harbi, K. S., & Imam, S. S. (2013). Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. Journal of Psychiatric Research, 47(5), 560–567.

He, X., Wu, X., She, S., Shao, Y., & Tao, J. (2016). Antidepressant effects of curcumin and HU-211 co-encapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression. International Journal of Nanomedicine, 11, 4975–4990.

Hines, D. J., & Kaplan, D. L. (2013). Poly(lactic-co-glycolic) acid-controlled-release systems: Experimental and modeling insights. Critical Reviews in Therapeutic Drug Carrier Systems, 30(3), 257–276.

Jani, P. H., Vanza, J. D., Pandya, N. M., & Tandel, H. J. (2019). Formulation of polymeric nanoparticles of antidepressant drug for intranasal delivery. Therapeutic Delivery, 10(11), 701–709.

Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2001). The prevalence and correlates of untreated serious mental illness. Health

Khawli, L. A., & Prabhu, S. (2013). Drug Delivery across the Blood–Brain Barrier. Molecular Pharmaceutics, 10(5), 1471–1472.

Lake, J., & Turner, M. S. (2017). Urgent Need for Improved Mental Health Care and a More Collaborative Model of Care. The Permanente Journal.

Lee, S., Patkar, A. A., & Han, C. (2010). Depression Research: Where Are We Now? Molecular Brain, 3, 8.

Martin, E. I., Ressler, K. J., Binder, E., & Nemeroff, C. B. (2009). The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology. The Psychiatric Clinics of North America, 32(3), 549–575.

Mayo Clinic Staff. (2019, September 12). An option if other antidepressants haven't helped. Mayo Clinic.

Mayo Clinic Staff. (2019, September 17). The Most Commonly Prescribed Type of Antidepressant. Mayo Clinic.

Murthy, S. K. (2007). Nanoparticles in Modern Medicine: State of the Art and Future Challenges. International Journal of Nanomedicine, 2(2), 129–141.

National Alliance on Mental Illness. (2019). Nearly 1 in 7 US Kids and Teens Have a Mental Health Condition -- Half Go Untreated, Study Says.

National Nanotechnology Initiative. (n.d.). Applications of nanotechnology.

Pardridge, W. M. (2012). Drug transport across the blood-brain barrier. Journal of Cerebral Blood Flow and Metabolism, 32(11), 1959-1972.

Pitt Medical Neuroscience. (n.d.). Neurophysiology Module 8. Monoamines.

Queensland Brain Institute - University of Queensland. (2022, July 25). What is the blood-brain barrier?

Rajaonarivony, M., Raharivelomanana, P., Vauthier, C., Couarraze, G., & Arnaud, P. (2016). Development of a new drug carrier made from alginate. Journal of Pharmaceutical Sciences, 105(2), 822-832.

Sarei, F., Fallahianfar, A. R., & Fattahi, A. (2013). Alginate nanoparticles as a promising adjuvant and vaccine delivery system. Indian Journal of Pharmaceutical Sciences, 75(4), 442-453.

Schaffer, D., Krysan, M., Lee, Y. M., & Wachter, K. (2013). Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without placebo control. International Clinical Psychopharmacology, 28(1), 12-19.

Shai, K., Dredze, M., Broniatowski, D. A., & Smith, M. R. (2021). Understanding side effects of antidepressants: Large-scale longitudinal study on social media data. JMIR Mental Health, 8(3), e26589.

World Health Organization. (n.d.). Mental Health. Retrieved March 21, 2023, from

Yale Medicine. (2021, June 17). How depression affects the brain. [Original source:]



How to Cite

Melendez, O. (2023). Comparing and contrasting the use of nanoparticle-assisted drug-delivery of antidepressants to that of the gold standard. Journal of Student Research, 12(3).



Review Articles